SH2B1: A Protein Regulator of Cell Signaling Pathways (G25970)

Target Name: SH2B1

NCBI ID: G25970

SH2B1

SH2B1: A Protein Regulator of Cell Signaling Pathways

SH2B1, also known as SH2B adaptor protein 1, is a protein that plays a crucial role in the regulation of cell signaling pathways. It is a member of the SH2B family of proteins, which are known for their ability to interact with and regulate the activity of various signaling molecules. SH2B1 has been shown to be involved in a wide range of cellular processes, including cell adhesion, migration, and survival.

One of the key functions of SH2B1 is its role in the regulation of the PI3K/Akt signaling pathway. This pathway is involved in a wide range of cellular processes, including cell survival, angiogenesis, and inflammation. SH2B1 has been shown to play a key role in the regulation of this pathway by interacting with and inhibiting the activity of the protein Pyknotin.

Another function of SH2B1 is its role in the regulation of the TGF-β signaling pathway. This pathway is involved in a wide range of cellular processes, including cell growth, differentiation, and inflammation. SH2B1 has been shown to play a key role in the regulation of this pathway by interacting with and inhibiting the activity of the protein Smad2.

In addition to its role in the regulation of these signaling pathways, SH2B1 has also been shown to be involved in the regulation of a wide range of cellular processes, including cell adhesion, migration, and survival. It has been shown to interact with and regulate the activity of a wide range of proteins, including the protein ZEB2, which is involved in cell adhesion and migration, and the protein NF-kappa-B, which is involved in inflammation and survival.

Given its involvement in a wide range of cellular processes, SH2B1 has been considered as a potential drug target. There are several studies have shown that SH2B1 can be targeted by small molecules, including inhibitors of the PI3K/Akt and TGF-β signaling pathways. These inhibitors have been shown to have a wide range of potential therapeutic applications, including the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In addition to its potential as a drug target, SH2B1 has also been shown to be a potential biomarker. Several studies have shown that SH2B1 levels can be accurately measured and correlated with the outcomes of various therapies, including cancer treatments. These studies have shown that SH2B1 levels can be reduced in response to cancer treatments, and that these reductions can be associated with improved outcomes.

Overall, SH2B1 is a protein that plays a crucial role in the regulation of cell signaling pathways. Its functions as a regulator of the PI3K/Akt and TGF-β signaling pathways have been well-studied, and its potential as a drug target and biomarker is widely recognized. Further research is needed to fully understand the role of SH2B1 in cellular processes and its potential as a therapeutic agent.

Protein Name: SH2B Adaptor Protein 1

Functions: Adapter protein for several members of the tyrosine kinase receptor family. Involved in multiple signaling pathways mediated by Janus kinase (JAK) and receptor tyrosine kinases, including the receptors of insulin (INS), insulin-like growth factor I (IGF1), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), platelet-derived growth factor (PDGF) and fibroblast growth factors (FGFs). In growth hormone (GH) signaling, autophosphorylated ('Tyr-813') JAK2 recruits SH2B1, which in turn is phosphorylated by JAK2 on tyrosine residues. These phosphotyrosines form potential binding sites for other signaling proteins. GH also promotes serine/threonine phosphorylation of SH2B1 and these phosphorylated residues may serve to recruit other proteins to the GHR-JAK2-SH2B1 complexes, such as RAC1. In leptin (LEP) signaling, binds to and potentiates the activation of JAK2 by globally enhancing downstream pathways. In response to leptin, binds simultaneously to both, JAK2 and IRS1 or IRS2, thus mediating formation of a complex of JAK2, SH2B1 and IRS1 or IRS2. Mediates tyrosine phosphorylation of IRS1 and IRS2, resulting in activation of the PI 3-kinase pathway. Acts as positive regulator of NGF-mediated activation of the Akt/Forkhead pathway; prolongs NGF-induced phosphorylation of AKT1 on 'Ser-473' and AKT1 enzymatic activity. Enhances the kinase activity of the cytokine receptor-associated tyrosine kinase JAK2 and of other receptor tyrosine kinases, such as FGFR3 and NTRK1. For JAK2, the mechanism seems to involve dimerization of both, SH2B1 and JAK2. Enhances RET phosphorylation and kinase activity. Isoforms seem to be differentially involved in IGF-I and PDGF-induced mitogenesis (By similarity)

The "SH2B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH2B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets